{
    "id": 31804,
    "fullName": "CDK13 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CDK13 positive indicates the presence of the CDK13 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 8621,
        "geneSymbol": "CDK13",
        "terms": [
            "CDK13",
            "CDC2L",
            "CDC2L5",
            "CHDFIDD",
            "CHED",
            "hCDK13"
        ]
    },
    "variant": "positive",
    "createDate": "12/16/2019",
    "updateDate": "12/16/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19536,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SR-4835 and Camptosar (irinotecan) combination treatment inhibited TP53 phosphorylation, induced apoptosis, and synergistically inhibited proliferation of a CDK12 and CDK13-positive triple-negative breast cancer cell line in culture (PMID: 31668947).",
            "molecularProfile": {
                "id": 34201,
                "profileName": "CDK12 pos CDK13 pos"
            },
            "therapy": {
                "id": 9060,
                "therapyName": "Irinotecan + SR-4835",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17144,
                    "pubMedId": 31668947,
                    "title": "Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31668947"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19534,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SR-4835 and Platinol (cisplatin) combination treatment inhibited TP53 phosphorylation, induced DNA damage and apoptosis, and synergistically inhibited proliferation of a CDK12 and CDK13-positive triple-negative breast cancer cell line in culture (PMID: 31668947).",
            "molecularProfile": {
                "id": 34201,
                "profileName": "CDK12 pos CDK13 pos"
            },
            "therapy": {
                "id": 9059,
                "therapyName": "Cisplatin + SR-4835",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17144,
                    "pubMedId": 31668947,
                    "title": "Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31668947"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19542,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SR-4835 treatment induced DNA damage, and inhibited proliferation of a CDK12 and CDK13-positive triple-negative breast cancer cell line in culture (PMID: 31668947).",
            "molecularProfile": {
                "id": 34201,
                "profileName": "CDK12 pos CDK13 pos"
            },
            "therapy": {
                "id": 9058,
                "therapyName": "SR-4835",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17144,
                    "pubMedId": 31668947,
                    "title": "Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31668947"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19537,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SR-4835 and Adriamycin (doxorubicin) combination treatment synergistically inhibited proliferation of a CDK12 and CDK13-positive triple-negative breast cancer cell line in culture (PMID: 31668947).",
            "molecularProfile": {
                "id": 34201,
                "profileName": "CDK12 pos CDK13 pos"
            },
            "therapy": {
                "id": 9061,
                "therapyName": "Doxorubicin + SR-4835",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17144,
                    "pubMedId": 31668947,
                    "title": "Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31668947"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19538,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SR-4835 and Lynparza (olaparib) combination treatment induced apoptosis and synergistically inhibited proliferation of a CDK12 and CDK13-positive triple-negative breast cancer cell line in culture (PMID: 31668947).",
            "molecularProfile": {
                "id": 34201,
                "profileName": "CDK12 pos CDK13 pos"
            },
            "therapy": {
                "id": 9062,
                "therapyName": "Olaparib + SR-4835",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17144,
                    "pubMedId": 31668947,
                    "title": "Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31668947"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 34200,
            "profileName": "CDK13 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34201,
            "profileName": "CDK12 pos CDK13 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}